Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

被引:13
作者
Toro, C
Rodés, B
Bassani, S
Jiménez, V
Tuset, C
Brugal, MT
de la Fuente, L
Soriano, V [1 ]
机构
[1] Hosp Carlos 3, Infect Dis Serv, Madrid, Spain
[2] Hosp Gen Univ, Serv Clin Anal, Valencia, Spain
[3] Agencia Salud Publ, Barcelona, Spain
[4] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
关键词
HTLV-2; IDUs; molecular epidemiology;
D O I
10.1016/j.jcv.2004.10.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: HTLV-2 infection is prevalent among intravenous drug users (IDUs), which often are coinfected with HIV-1. Two main subtypes, HTLV-2a and -2b. have been described among European IDUs, with a characteristically geographic distribution: IIa in northern Europe and IIb in the south. Although frequent traveling within Europe might have favoured a wide dissemination of diverse HTLV-2 variants, HTLV-2b was so far the only subtype reported in Spain. Objective: To investigate the current molecular epidemiology of HTLV-2 in Spain. Study design Twenty-six new HTLV-2 strains isolated from IDUs over the last I I years in different geographic regions were examined. The HTLV LTR regon (620 bp) was sequenced and phylogenetic analyses were performed. Endonuclease restriction sites were examined to further characterize the HTLV-2 subgroup. Results: All 26 individuals infected with HTLV-2 showed viruses belonging to the HTLV-2 b4 clade and were closely related to the previously reported HTLV-2 Spanish and Italian IDU isolates. Conclusions: HTLV-2 Subtype b4 continues to be the only HTLV-2 subgroup recognized so far in Spain and no introduction of other HTLV-2 variants has occurred over the last 11 years. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 23 条
[1]  
Andersson Soren, 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P280
[2]  
BARRIO G, 1993, MED CLIN-BARCELONA, V101, P344
[3]   Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1 [J].
Bovolenta, C ;
Pilotti, E ;
Mauri, M ;
Panzeri, B ;
Sassi, M ;
Dall'Aglio, P ;
Bertazzoni, U ;
Poli, G ;
Casoli, C .
JOURNAL OF IMMUNOLOGY, 2002, 169 (08) :4443-4449
[4]   Neurologic consequences of HTLV-II infection in injection-drug users [J].
Dooneief, G ;
Marlink, R ;
Bell, K ;
Marder, K ;
Renjifo, B ;
Stern, Y ;
Mayeux, R .
NEUROLOGY, 1996, 46 (06) :1556-1560
[5]   High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland [J].
Egan, JF ;
O'Leary, B ;
Lewis, MJ ;
Mulcahy, F ;
Sheehy, N ;
Hasegawa, H ;
Fitzpatrick, F ;
O'Connor, JJ ;
O'Riordan, J ;
Hall, WW .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (08) :699-705
[6]   Human retroviruses after 20 years: a perspective from the past and prospects for their future control [J].
Gallo, RC .
IMMUNOLOGICAL REVIEWS, 2002, 185 :236-265
[7]  
Goubau P, 1996, J ACQ IMMUN DEF SYND, V13, P68
[8]   Human T-lymphotropic virus type II RFLP subtypes a0 and b4/b5 are associated with different demographic and geographic characteristics in the United States [J].
Liu, H ;
Leung, P ;
Glynn, S ;
Murphy, EL .
VIROLOGY, 2001, 279 (01) :90-96
[9]   Epidemiologic features of HTLV-II: Serologic and molecular evidence [J].
Lowis, GW ;
Sheremata, WA ;
Minagar, A .
ANNALS OF EPIDEMIOLOGY, 2002, 12 (01) :46-66
[10]   Molecular epidemiology of HTLV-II among United States blood donors and intravenous drug users:: An age-cohort effect for HTLV-II RFLP type aO [J].
Murphy, EL ;
Mahieux, R ;
de Thé, G ;
Tekaia, F ;
Ameti, D ;
Horton, J ;
Gessain, A .
VIROLOGY, 1998, 242 (02) :425-434